Table 2.
Improvements from baseline to 6-month follow-up in symptoms and quality of life (iterative matching sample).
| HESr | WW | p Value | |||||
|---|---|---|---|---|---|---|---|
| N | Mean (SD) | % * | N | Mean (SD) | % * | ||
| IPSS total | 634 | 3.8 (4.4) | 25.0 | 91 | 2.2 (4.5) | 15.3 | 0.002 |
| IPSS voiding subscore | 634 | 2.1 (2.9) | 24.4 | 91 | 1.0 (2.8) | 12.2 | 0.001 |
| IPSS storage subscore | 634 | 1.7 (2.1) | 25.8 | 91 | 1.2 (2.1) | 19.4 | 0.039 |
| BII total | 632 | 1.8 (2.4) | 30.0 | 91 | 1.0 (2.2) | 17.5 | <0.001 |
| Physical discomfort | 631 | 0.4 (0.8) | 26.7 | 91 | 0.3 (0.8) | 20.0 | 0.119 |
| Worry about the health | 631 | 0.5 (0.9) | 31.3 | 91 | 0.3 (0.7) | 18.8 | 0.002 |
| Bothered with urination | 631 | 0.4 (0.8) | 28.6 | 91 | 0.2 (0.7) | 15.4 | 0.015 |
| Daily activity limitation | 631 | 0.5 (0.8) | 35.7 | 91 | 0.2 (0.8) | 15.4 | 0.002 |
HESr: hexanic extract of Serenoa repens; WW: watchful waiting; IPSS: International Prostate Symptom Score; BII: Benign Prostatic Hyperplasia Impact Index; * Percentage of improvement over initial values.